Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

9. Check if this filing amends a previously filed version of this report

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---Centers for Disease Control and Prevention
---FDA
---Health Resources and Services Administration (HRSA)


FY 2026 Appropriations for Specific Issues
---Antimicrobial Resistance (General)
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Funding for Strategic National Stockpile
---Pandemic Preparedness
---Reauthorization of PAHPA
---Vaccine Access & Compensation

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Antitrust Legislation
---Oversight Pharmacy Benefit Managers
---General

Artificial Intelligence (AI)

Bayh-Dole Act/Tech Transfer
---Bayh-Dole Act
---March-In Rights

Data Privacy
---A bill to prohibit contracting with certain biotechnology providers, and for other purposes
---American Privacy Rights Act
---Bio COMPETES (Draft)
---BIOSECURE Act
---Executive Order on Preventing Access to Americans Data from Foreign Adversaries Act


Drug Patenting
---A bill to address patent thickets
---S.1546/H.R.3152 Patent Eligibility Restoration Act
---Affordable Prescriptions for Patients Act
---FTC Orange Book Delisting Initiative
---S.1097 Interagency Patent Coordination and Improvement Act of 2025
---S.2658 Medication Affordability and Patient Integrity Act
---S.1041 Affordable Prescriptions for Patients Act
---S.2276 ETHIC Act
---Dept of Commerce Patent Valuation Fee Proposal
---S.43 Skinny Labels, Big Savings Act
---S.527 Prescription Pricing for the People Act
---S.1096 Preserve Access to Affordable Generics and Biosimilars Act
---Prohibiting Adversarial Patents Act
---H.R.3160/S.1553 PREVAIL Act
---Patent Tax/fees

Foreign Drug Data Protection Law
---BIOSECURE Act
---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern
---House GOP RFI on Supply Chain

Intellectual Property Enforcement
---China

Patent Reform
---Interagency Patent Coordination and Improvement Act
---Patent Eligibility Restoration Act (PERA)
---Patent Litigation Reform
---Prohibiting Adversarial Patents Act (PAPA)
---Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act

Patenting of Biological Inventions
---Patent Eligibility Restoration Act (PERA)
---Section 101 Modernization

World Intellectual Property Office (WIPO)
---Treaty on Intellectual Property, Genetic Resources, and Associated Traditional Knowledge

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---ASPR
---Centers for Disease Control and Prevention
---FDA
---Health Resources and Services Administration (HRSA)
---HHS Office of Infectious Disease and HIV/AIDS Policy
---National Institute of Health

FY 2026 Appropriations for Specific Issues
---Alternative Funding Programs
---Antimicrobial Resistance (General)
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---CICP
---Creating Hope Reauthorization Act
---Drug Pricing
---Funding for Strategic National Stockpile
---Funding for Women's Health Research
---Implementation of the Inflation Reduction Act (IRA)
---Influenza Planning & Response
---MCM PRV Reauthorization
---Pandemic Preparedness -R&D Funding for Medical Countermeasures
---PPRV
---Prescription Drug User Fee Act (PDUFA) VII Implementation
---Project Bioshield
---Reauthorization of PAHPA
---Vaccines and Infectious Diseases
---Vaccine Injury Compensation Program
---Section 317 Immunization Program

HR 5256 Affording Care for Communities and Ensuring a Strong Safety-Net Act (340B ACCESS Act).
---340B Accountability Act
---Executive Order on Access to Affordable Life-Saving Medications
---Program Implementation & Oversight
---PROTECT 340B Act
---SUSTAIN 340B Act

Accelerated Approval

Artificial Intelligence (AI)

Alternative Funding Programs

Biodefense Research, Development and Procurement Issues
---BIOSECURE Act
---Disease X Act
---Gain of function (Viral Gain of Function Research Moratorium Act, SAFE Risky Research Act)
---House GOP RFI on Supply Chain
---Implementation of Medical Countermeasure Innovation Act
---Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act
---Improving Data Accessibility Through Advancements (DATA) in Public Health Act
---MCM PRV Program Reauthorization
--- National Defense Authorization Act 2026
---Reasonable Pricing Clauses in BARDA Contracts
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---Risky Research Review Act
---Tropical Disease Priority Review Voucher (PRV) Program
---VICP Loopholes
---WHO Pandemic Preparedness Accord

Biosimilars
---Biosimilar Copay
---Biosimilar Red Tape Elimination Act
---Interchangeability and Pharmacy Substitution
---Preserve Access to Affordable Generics and Biosimilars Act
---Reimbursement

Cell & Gene Therapy

Data Privacy
---American Privacy Rights Act
---BIOSECURE Act
---Clinical Trial Data in China

Diagnostics and Personalized Medicine Regulation and Oversight

Diversity & Inclusion
---Decentralized Clinical Trials
---H.R. 3521, Clinical Trial Modernization Act

Drug Evaluation and Review
---FDA Hiring Flexibility
---Promising Pathway Act

Drug Importation

Drug Manufacturing, Quality & Distribution
---Advanced Manufacturing
---Drug Shortages
---Supply Chain Integrity and Traceability

Drug Patenting
---A bill to address patent thickets
---A bill to establish special rules relating to information provided with respect to drug applications concerning method of use patents
---Affordable Prescriptions for Patients Act
---Interagency Patent Coordination and Improvement Act
---Medication Affordability and Patient Integrity Act
---Patent Thickets
---Prescription Pricing for the People Act
---Preserve Access to Affordable Generics and Biosimilars Act
---Restrictions on Intellectual Property Rights

Drug Pricing
---H.R.946: ORPHAN Cures Act
---H.R. 1492 Ensuring Pathways to Innovative Cures (EPIC) Act
---H.R.1672 Maintaining Investments and New Innovation (MINI) Act
---S.2082 Stronger Patents Act
---Access to Innovative Treatments Act
---Affordable Prescriptions for Patients Act
---Biosimilar Red Tape Elimination Act
---CMMI Authority
---COVID-19 Pricing-Related Provisions
---DRUG Act
---Ensuring Timely Access to Generics
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Inflation Reduction Act (IRA)
---Increasing Transparency in Generic Drug Application
---Interagency Patent Coordination and Improvement Act
---Lowering Drug Costs for American Families Act
---Mandating Exclusive Review of Individual Treatments (MERIT) Act
---Medicare Drug Price Negotiation Act
---Medicare Negotiation and Competitive Licensing Act
---Modernizing and Ensuring PBM Accountability (MEPA) Act
---Most Favored Nation
---National Coverage Determination
---Patient Cost-Sharing and Implementation
---PBM Reform
---Pharmacy Benefit Manager Transparency Act
---Prescription Drug Price Relief Act
---Prescription Pricing for the People Act
---Preserve Access to Affordable Generics and Biosimilars Act
---Protecting Patient Access to Cancer and Therapies
---Strengthening Innovation in Medicare and Medicaid Act
---HR 1 One Big Beautiful Bill Act

Efforts to expand the Bio Economy & Bio Manufacturing

Foreign Drug Data Protection Laws
---BIOSECURE Act
---A bill to prohibit contracting with certain biotechnology providers, and for other purposes.

Generic Drug Entry
---Generic Drug Application Review Reforms
---Incentives for Generic Entry

Issues Relating to Medical Research and Animal Testing
---FDA Modernization Act 3.0

Medicaid
---Alternative Payment Arrangements for Gene Therapies
---Coverage of Accelerated Approval Products
---Drug Benefit Design
---Drug Rebate Program Rule
---Modernizing and Ensuring PBM Accountability (MEPA) Act
---Pharmacy Benefit Manager Transparency Act of 2025
---The Medicaid VBPs for Patients (MVP) Act
---Value-Based Purchasing (VBP) Rule

National Defense
---National Defense Authorization Act of 2026

National Security
---BIOSECURE Act
---Clinical Trial Data in China
---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern


Opioid Crisis
---SUPPORT Act

Orphan Drug Issues
---H.R.946: ORPHAN Cures Act
---H.R.1262: Give Kids a Chance Act
---Finding Orphan-Disease Remedies with Antifungal Research and Development (FORWARD) Act
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Innovation in Pediatric Drugs Act of 2023
---Orphan Drug Tax Credit
---Retaining Access and Restoring Exclusivity (RARE) Act

Pandemic Preparedness
---Drug Supply Chain Management
---Implementation of the Prepare for and Respond to Existing Viruses, Emerging New Threats and (PREVENT) Pandemics Act
---Medical Countermeasures PRV Reauthorization
---Supply Chain Issues
---Temporarily Refundable R&D Credit
---WHO Pandemic Preparedness Accord

Precision Medicine Initiative

Reimbursement and Coverage of Innovative Products
---HR 3493 Global Fairness in Drug Pricing Act
---CMMI Authority
---HELP Copays Act
---National Coverage Determination
---SAFE STEP Act
---Step Therapy
---Support of Patient Premiums and Cost-Sharing Obligations
---Mandating Exclusive Review of Individual Treatments (MERIT) Act

Vaccines and Infectious Diseases
---Adult Immunization
---Antimicrobial Resistance (General)
---Let Injured Americans Be Legally Empowered (LIABLE) Act
---MCM Manufacturing & Capacity
---MCM R&D Incentives
---SAFE STEP Act
---Vaccine and Antimicrobial Resistance Product Development and Incentives
---Vaccine Injury Compensation Modernization Act
---Vaccine Injury Compensation Program
---Vaccine Quality Measure
---Vaccine Safety
---Vaccine Safety Net and Vaccine Infrastructure
---Value of Vaccines and Vaccine Confidence
---HR 3701 Family Vaccine Protection Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS), Commerce - Dept of (DOC), U.S. Trade Representative (USTR), Natl Security Council (NSC), Natl Economic Council (NEC), Treasury - Dept of, White House Office, Council of Economic Advisers (CEA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HOM

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---Centers for Disease Control and Prevention Vaccine Programs
---Health Resources and Services Administration (HRSA)
---HHS Office of Infectious Disease and HIV/AIDS Policy

FY 2026 Appropriations for Specific Issues
---Antimicrobial Resistance (General)
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Funding for Strategic National Stockpile
---MCM PRV Reauthorization
---Reauthorization of PAHPA
---VICP/CICP
---Prescription Drug User Fee Act (PDUFA) VII Implementation
---Advanced Research Projects Agency for Health (ARPA-H) Act
---Funding for Women's Health Research
---Pandemic Preparedness -R&D Funding for Medical Countermeasures


Biodefense Research, Development and Procurement Issues (Non-Funding)
---BIOSECURE Act
---Risky Research Review Act
---Bio COMPETES (Draft)
---Gene Editing
---MCM PRV Program
---Reauthorization of Pandemic and All-Hazards Preparedness and Advancing (PAHPA)
---WHO Pandemic Preparedness Accord
---Executive Order on Achieving Efficiency Through State and Local Preparedness
---Executive Order on Withdrawing the United States from the World Health Organization
---HHS Reorganization
---State Strategic Stockpile Act
---National Defense Authorization Act 2026

Pandemic Preparedness
---Drug Supply Chain Management
---Implementation of the Prepare for and Respond to Existing Viruses, Emerging New Threats and (PREVENT) Pandemics Act
---Supply Chain Issues
---Temporarily Refundable R&D Credit
---Medical Countermeasure Priority Review Voucher Reauthorization

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MED

16. Specific lobbying issues

FY 2026 Appropriations for Agencies
---Centers for Disease Control and Prevention
---FDA
---Health Resources and Services Administration (HRSA)
---HHS Office of Infectious Disease and HIV/AIDS Policy
---National Institute of Health
---BARDA
---ASPR

FY 2026 Appropriations for Specific Issues
---Antimicrobial Resistance (General)
---Advanced Research Projects Agency for Health (ARPA-H) Act
---Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---Funding for Strategic National Stockpile
---Implementation of the Inflation Reduction Act (IRA)
---MCM PRV Reauthorization
---Reauthorization of PAHPA
---Vaccine Injury Compensation Program (VICP)/CICP
---Funding for Medical Countermeasures
---Pandemic Flu
---Pandemic Preparedness -R&D Funding for Medical Countermeasures

Antimicrobial Resistance

Biodefense Research, Development and Procurement Issues
---Bio COMPETES (Draft)
---Gene Editing
---MCM PRV Program
---HHS Reorganization


CDC Reform

Pandemic Preparedness
---MCM PRV Reauthorization

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

FY 2026 Appropriations for Specific Issues
---Drug Pricing
---Antimicrobial Resistance (General)
---Vaccines and Infectious Diseases
---Alternative Funding Programs
---Pandemic Preparedness -R&D Funding for Medical Countermeasures

340B Drug Discount Program
---Executive Order on Access to Affordable Life-Saving Medications
---Program Implementation & Oversight
---PROTECT 340B Act


Accelerated Approval

Antimicrobial Resistance

Artificial Intelligence (AI)

Alternative Funding Programs

Biosimilars
---Biosimilar Copay
---BSUFA Negotiations
---Implementation of BSUFA Agreement
---Interchangeability and Pharmacy Substitution
---Reimbursement
---Biosimilars Red Tape Elimination Act

Cell & Gene Therapy
---H.R.1672 -Maintaining Investments and New Innovation (MINI) Act

Clinical Trial Data in China

Diversity & Inclusion
---Decentralized Clinical Trials

Drug Evaluation and Review
---Promising Pathway Act
---FDA Hiring Flexibility

Drug Importation

Drug Manufacturing, Quality & Distribution
---Advanced Manufacturing
---Drug Shortages
---Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy
---Supply Chain Integrity and Traceability
---Compounded Medicines

Drug Patenting
---Interagency Patent Coordination and Improvement Act
---Prescription Pricing for the People Act
---Preserve Access to Affordable Generics and Biosimilars Act
---Restrictions on Intellectual Property Rights
---Patent Thickets
---HR 1 One Big Beautiful Bill Act


Drug Pricing
---H.R.946: ORPHAN Cures Act
---H.R. 1492 Ensuring Pathways to Innovative Cures (EPIC) Act
---H.R.1672 Maintaining Investments and New Innovation (MINI) Act
---Interagency Patent Coordination and Improvement Act of 2025
---PBM Reform
---Prescription Drug Pricing for the People Act
---Pharmacy Benefit Manager Transparency Act
---Preserve Access to Affordable Generics and Biosimilars Act
---Stop STALLING Act
---CMMI Authority
---Implementation of the Inflation Reduction Act (IRA)
---Patient Cost-Sharing and Implementation
---Strengthening Innovation in Medicare and Medicaid Act
---Most Favored Nation

Foreign Drug Data Protection Laws
---Executive Order on Preventing Access to Americans Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern

Medicaid
---Pharmacy Benefit Manager Transparency Act
---Alternative Payment Arrangements for Gene Therapies
---Average Manufacturer Price Calculations
---Coverage of Accelerated Approval Products
---Drug Benefit Design
---Encouraging Innovation Benefit Design to Lower Costs for Seniors Act
---Medicaid Drug Rebate Program
---Most Favored Nation
---Pricing and Rebates
---Value-Based Purchasing (VBP) Rule

National Defense
---National Defense Authorization Act of 2026

Opioid Crisis
---SUPPORT Act
---Non-Opioid Analgesics

Orphan Drug Issues
---H.R.946: ORPHAN Cures Act
---S. 946 ORPHAN Cures Act
---Give Kids A Chance Act
---Pediatric Priority Review Voucher Program Reauthorization
---Implementation of the Inflation Reduction Act (IRA) of 2022
---Orphan Drug Tax Credit

Pandemic Preparedness
---Drug Supply Chain Management
---House GOP RFI on Supply Chain
---Monoclonal Antibody Coverage and Utilization
---Restrictions on Intellectual Property Rights
---Supply Chain Issues
---WHO Pandemic Preparedness Accord
---Medical Countermeasure Priority Review Voucher Reauthorization

Precision Medicine Initiative

Reimbursement and Coverage of Innovative Products
---HELP Copays Act
---Administration Rebate Rule
---CMMI Authority
---Medicare Part B Physician-Administered Products
---National Coverage Determination
---Patient Cost-Sharing and Smoothing
---Support of Patient Premiums and Cost-Sharing Obligations

Vaccines and Infectious Diseases
---Adult Immunization
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act
---Countermeasures Injury Compensation Program
---Vaccine Injury Compensation Program
---Maternal Immunization
---MCM Manufacturing & Capacity
---MCM PRV Reauthorization
---Monoclonal Antibody Coverage and Utilization
---National Coverage Determination
---Vaccine Safety and Quality
---Vaccine Safety Net and Vaccine Infrastructure
---Value of Vaccines and Vaccine Confidence

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), Natl Security Council (NSC), Natl Economic Council (NEC), Council of Economic Advisers (CEA), Treasury - Dept of, Commerce - Dept of (DOC), U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code SMB

16. Specific lobbying issues

Capital Formation Incentives
---Accredited Investor Definition Review Act
---Helping Startups Continue to Grow Act
---Small Entity Update Act

Capital Market Enhancements

Small Business Innovation Research (SBIR) Program
---Reauthorization of SBIR and STTR
---Implementation of the SBIR and STTR Extension Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Small Business Administration (SBA)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

FY 2026 Appropriations for Specific Issues
---Vaccines and Infectious Diseases
---VICP/CICP

Capital Formation Incentives
---Helping Startups Continue to Grow Act
---Small Entity Update Act
---Expanding Access to Capital Act
---Equal Opportunity for All Investors Act

Orphan Drug Issues
---ORPHAN Cures Act
---Give Kids a Chance Act
---Cameron's Law

Pandemic Preparedness

Renewable Chemicals/Bio-based Products

Research & Development Tax Credit Reforms
---American Innovation and R&D Competitiveness Act
---American Innovation and Jobs Act
---Expensing of R&D Expenditures
---R&D Payroll Credit
---Net Operating Loss Legislation
---HR 1 One Big Beautiful Bill Act

Vaccines and Infectious Disease
---Vaccine Injury Compensation Modernization Act
---Vaccine Access Improvement Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

CFIUS and Foreign Investment

Drug Importation

Drug Pricing
---Reference Pricing in Drug Reimbursement
---Most Favored Nation

Foreign Agricultural Biotechnology Laws and Regulations

Foreign Drug Data Protection Laws
---BIOSECURE Act
---Protecting Americans Data from Foreign Adversaries Act
---A bill to prohibit contracting with certain biotechnology providers, and for other purposes.
---Bio COMPETES (Draft)

Genetically Engineered (GE) Animals

Genetically Engineered (GE) Plants

Global Supply Chain Resiliency
---B5 Coalition on Supply Chain Resiliency
---Temporarily Refundable R&D Credit

Intellectual Property International Enforcement
---China

Synthetic Biotech

Tariffs

Trade Relations
---Section 232
---World Intellectual Property Office (WIPO) -Treaty on Intellectual Property, Genetic Resources, and Associated Traditional Knowledge

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), Natl Security Council (NSC), Natl Economic Council (NEC), Council of Economic Advisers (CEA), Commerce - Dept of (DOC), Treasury - Dept of, U.S. Trade Representative (USTR)

18. Name of each individual who acted as a lobbyist in this issue area

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different than line 20)

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
No Yes